Tirzepatide Beats Semaglutide for Weight Loss in Head-to-Head Meta-Analysis

What the researchers found

Tirzepatide demonstrated significantly superior weight loss compared to semaglutide across 7 studies (28,980 participants). The pooled standardized mean difference was 0.75 (95% CI: 0.52–0.92) favoring tirzepatide.

At 6 months, tirzepatide achieved a mean difference of 1.33 percentage points greater weight reduction (95% CI: 0.58–2.08). Participants on tirzepatide had significantly higher odds of achieving ≥10% weight loss compared to semaglutide (OR: 0.21, 95% CI: 0.06–0.78). However, heterogeneity was very high across studies (I² >90%).

Why it matters

With tirzepatide and semaglutide both becoming blockbuster weight-loss drugs, patients and doctors need to know which works better. This is one of the first meta-analyses to pool head-to-head comparison data, providing stronger evidence than individual studies alone. The finding that tirzepatide's dual-receptor approach outperforms GLP-1-only targeting has implications for drug selection and future drug development.

How the study worked

Systematic review and meta-analysis of studies directly comparing tirzepatide and semaglutide for weight management. Four databases (PubMed, EMBASE, Web of Science, Cochrane Library) were searched through April 2025. Seven studies met inclusion criteria: 5 observational studies and 2 randomized controlled trials, with follow-up ranging from 6 to 12 months. Data were pooled using random-effects models in Review Manager 5.4.1.

What this study cannot tell us

High heterogeneity (I² >90%) indicates substantial variation across studies, weakening the pooled estimates. Only 2 of 7 studies were randomized controlled trials; the remaining 5 were observational, introducing potential confounding. Follow-up was limited to 6–12 months. Different doses and formulations of both drugs were used across studies. Safety and tolerability were not comprehensively compared.

How to read the evidence

This is a systematic review and meta-analysis, generally considered strong evidence. However, the inclusion of mostly observational studies (5 of 7) and very high heterogeneity (I² >90%) reduce confidence. More large, well-designed RCTs directly comparing the drugs are needed.

When this study was published

Published in 2025, this is a very timely meta-analysis addressing one of the most commercially and clinically important questions in current pharmacotherapy.

The bigger picture

The incretin-based obesity drug market is the fastest-growing pharmaceutical segment in history. While both semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) have shown remarkable efficacy individually, the relative advantage of dual GIP/GLP-1 receptor agonism over GLP-1 alone is a critical question for the field. This meta-analysis adds to growing evidence that dual-receptor targeting provides additional weight-loss benefit, which may drive development of more multi-receptor peptide drugs.

Questions still open

• Does tirzepatide's weight loss advantage over semaglutide persist beyond 12 months?
• At equivalent maximum doses, how do the side effect profiles compare between the two drugs?
• Is tirzepatide's superiority driven primarily by the additional GIP receptor activation, or by other pharmacokinetic differences?

Common questions

Read the original research

Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.

Cureus, 17(6), e86080

Citation

Munawar, Nazish; Mahato, Aakash; Rawat, Anurag; Gill, Fahad Shaukat; Kumar, Daksh; Katwal, Susant; Wei, Calvin R; Ali, Neelum. (2025). Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.. Cureus, 17(6), e86080. https://doi.org/10.7759/cureus.86080